Literature DB >> 1315130

Detection of human papillomavirus infection in diseased and nondiseased sites of the respiratory tract in recurrent respiratory papillomatosis patients by DNA hybridization.

S Pignatari1, E M Smith, S D Gray, C Shive, L P Turek.   

Abstract

We examined 12 recurrent respiratory papillomatosis patients, who were undergoing treatment for recurrence of their disease, for the presence of human papillomavirus (HPV). Biopsies were obtained from their respiratory papillomas and nondiseased sites (NDS) of the respiratory tract: the nasopharynx, posterior tonsillar pillar, aryepiglottic fold, cervical trachea, intrathoracic trachea, and bronchi. The presence of HPV DNA was determined by using the ViraPap/ViraType DNA hybridization procedure. Two thirds of the patients were infected with HPV 6/11 in either the diseased papilloma or NDS: 50% of patients with papilloma specimens typed positive (6 of 12), and 40% of the patients typed HPV-positive in one or more biopsies from the NDS (4 of 10). No single NDS was more likely to be infected with HPV than any other. No oncogenic HPV types 16/18 or 31/33/35 were detected in the papillomas or NDS of these patients. Only patients with multiple, and not isolated, papilloma involvement were found to harbor HPV DNA in NDS; and 80% of those with infected NDS, compared to 20% of those without infected NDS, required a shorter (no more than 3 months) surgical treatment interval. Our results show that HPV infection frequently persists in adjacent, clinically normal sites, and suggest that the extent of NDS involvement may predict both the extent of disease and the likelihood of recurrence.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1315130     DOI: 10.1177/000348949210100506

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  16 in total

1.  [Treatment outcomes of recurrent respiratory papillomatosis : Retrospective analysis of juvenile and adult cases. German version].

Authors:  V-A Papaioannou; A Lux; S Voigt-Zimmermann; C Arens
Journal:  HNO       Date:  2017-11       Impact factor: 1.284

2.  Treatment outcomes of recurrent respiratory papillomatosis : Retrospective analysis of juvenile and adult cases.

Authors:  V-A Papaioannou; A Lux; S Voigt-Zimmermann; C Arens
Journal:  HNO       Date:  2018-01       Impact factor: 1.284

Review 3.  [Current therapeutic options for recurrent respiratory papillomatosis].

Authors:  K Huber; H Sadick; K Götte
Journal:  HNO       Date:  2005-11       Impact factor: 1.284

Review 4.  The known unknowns of HPV natural history.

Authors:  Patti E Gravitt
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

Review 5.  Recurrent respiratory papillomatosis: an overview.

Authors:  Qingliang Xue; Haitao Wang; Jianxin Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-28       Impact factor: 3.267

6.  Lack of methylation in the upstream region of human papillomavirus type 6 from aerodigestive tract papillomas.

Authors:  Agustín Enrique Ure; Ola Forslund
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

Review 7.  A possible role for human papillomaviruses in head and neck cancer.

Authors:  B M Steinberg; T P DiLorenzo
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

8.  Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis.

Authors:  Irena Hočevar-Boltežar; Mojca Matičič; Maja Sereg-Bahar; Nina Gale; Mario Poljak; Boštjan Kocjan; Miha Zargi
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-26       Impact factor: 2.503

Review 9.  Immunological tolerance of low-risk HPV in recurrent respiratory papillomatosis.

Authors:  R Ivancic; H Iqbal; B deSilva; Q Pan; L Matrka
Journal:  Clin Exp Immunol       Date:  2019-10-31       Impact factor: 4.330

10.  The biology of papillomavirus latency.

Authors:  Gareth Adam Maglennon; John Doorbar
Journal:  Open Virol J       Date:  2012-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.